Showing results (1-10 of 327) with videos related to

Sort By:
Pageof 33
Rheumatology (Oxford, England)|December 23, 2017
How to prevent allopurinol hypersensitivity reactions?Lisa K Stamp, Murray L Barclay
The Journal of Rheumatology|January 15, 2025
Inpatient Management of Gout: Serum Urate Testing and Allopurinol Dose AdjustmentKate Alfeld, Murray L Barclay, Richard McNeill, et al.
Arthritis and Rheumatism|November 1, 2008
Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritisJudith M Dalrymple, Lisa K Stamp, John L O'Donnell, et al.
Arthritis and Rheumatism|February 1, 2011
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairmentLisa K Stamp, John L O'Donnell, Mei Zhang, et al.
Arthritis and Rheumatism|January 30, 2010
Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapyLisa K Stamp, John L O'Donnell, Peter T Chapman, et al.
British Journal of Clinical Pharmacology|October 10, 2015
Predicting allopurinol response in patients with goutDaniel F B Wright, Stephen B Duffull, Tony R Merriman, et al.
British Journal of Clinical Pharmacology|July 13, 2013
Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell typesJulia Korell, Stephen B Duffull, Judith M Dalrymple, et al.
Arthritis and Rheumatism|August 1, 2009
Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatmentLisa K Stamp, John L O'Donnell, Peter T Chapman, et al.
The Journal of Rheumatology|October 4, 2011
Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritisLisa K Stamp, Murray L Barclay, John L O'Donnell, et al.
Clinical Pharmacokinetics|March 14, 2013
A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cellsJulia Korell, Lisa K Stamp, Murray L Barclay, et al.
Pageof 33